This mutation, characterized by a valine-to-glutamic acid substitution at codon 600 of the BRAF gene, leads to constitutive activation of the mitogen-activated protein kinase (MAPK) signaling pathway, driving uncontrolled cell proliferation and tumor progression [2,3]. The gene discussed is BRAF; the disease is neoplasm.